<DOC>
	<DOCNO>NCT01519700</DOCNO>
	<brief_summary>The study ass efficacy EP2006 compare Filgrastim respect mean duration severe neutropenia treatment myelosuppressive chemotherapy breast cancer patient .</brief_summary>
	<brief_title>Phase III Study Comparing Efficacy Safety EP2006 Filgrastim</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Patients histologically proven breast cancer , eligible neoadjuvant adjuvant myelosuppressive chemotherapy 2 . Women â‰¥ 18 year age 3 . Estimated life expectancy six month 1 . Previous concurrent malignancy except noninvasive nonmelanoma skin cancer , situ carcinoma cervix , solid tumor treat curatively , without evidence recurrence least ten year prior study entry 2 . Any serious illness medical condition may interfere safety , compliance , response product investigation evaluation , e.g . : Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Filgrastim</keyword>
	<keyword>G-CSF , neutropenia</keyword>
	<keyword>supportive care</keyword>
	<keyword>breast cancer</keyword>
</DOC>